CXCR3 Provides a Competitive Advantage for Retention of <i>Mycobacterium tuberculosis</i>-Specific Tissue-Resident Memory T Cells Following a Mucosal Tuberculosis Vaccine.

Armitage, Ellis; Quan, Diana; Flórido, Manuela; Palendira, Umaimainthan; Triccas, James A; Britton, Warwick J

CXCR3 Provides a Competitive Advantage for Retention of Mycobacterium tuberculosis-Specific Tissue-Resident Memory T Cells Following a Mucosal Tuberculosis Vaccine.

Armitage, Ellis; Quan, Diana; Flórido, Manuela; Palendira, Umaimainthan; Triccas, James A; Britton, Warwick J.

Afiliação

Armitage E; Centenary Institute, The University of Sydney, Sydney, NSW 2006, Australia.
Quan D; Centenary Institute, The University of Sydney, Sydney, NSW 2006, Australia.
Flórido M; Centenary Institute, The University of Sydney, Sydney, NSW 2006, Australia.
Palendira U; Centenary Institute, The University of Sydney, Sydney, NSW 2006, Australia.
Triccas JA; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Britton WJ; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Vaccines (Basel) ; 11(10)2023 Sep 29.

Article em En | MEDLINE | ID: mdl-37896952